Summit Therapeutics

Summit Therapeutics

Yahoo Finance • yesterday

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026

Recent $2 Billion Strategic Equity Investment in Summit by AstraZeneca and Summit's Expanding Network of Clinical Collaborations Underscore Confidence in Ivonescimab's Potential Ivonescimab Global Clinical Development Program Continues to... Full story

Yahoo Finance • 6 days ago

Summit Therapeutics (SMMT) Could Be 46% Undervalued On New Cancer Trials And AI Deal

Summit Therapeutics (SMMT) has packed October with pipeline moves, including a new Phase II kidney cancer study, a Phase II/III biliary tract cancer trial and an AI pathology research deal. Those October trial launches and the AI patholog... Full story

Yahoo Finance • 11 days ago

Summit Therapeutics reports survival benefit for cancer drug in trial

[Male doctor visiting female cancer patient with care and compassion in hospital room. Oncology support medical consultation healthcare and hope. Doctor reporting medical test results to the patient] chanakon laorob Summit Therapeutics (S... Full story

Yahoo Finance • 13 days ago

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology SEOUL, South Korea, Oct. 24, 2026 /PRNewswire/ -- Lunit Inc. (KRX: 328130) and Su... Full story

Yahoo Finance • 20 days ago

Summit Therapeutics (SMMT) Stock Fair Value Edges Higher After AstraZeneca Deal And Trial Focus

The fair value estimate for Summit Therapeutics has shifted slightly, from about US$29.21 per share to about US$30.07 per share, putting fresh focus on how analysts are framing the stock today. Recent research ties that move to the US$2b A... Full story

Yahoo Finance • 20 days ago

Catalyst Watch: Meta earnings, Kroger event, and Black Monday turns 39

[bad day at wall street] franckreporter Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - OCTOBER... Full story

Yahoo Finance • 29 days ago

AstraZeneca (LSE:AZN) Stock Looks Reasonable Based On Current Earnings

AstraZeneca has been busy on the deal and research front, yet the more pressing question for you today is whether the current share price can be explained by the company's earnings power. Over the past 5 years the stock has gained 49.2%,... Full story

Yahoo Finance • last month

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

MIAMI, October 05, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continu... Full story

Yahoo Finance • last month

Trending stocks this week as markets weigh jobs data, yields

[Wall street sign in New York with New York Stock Exchange background] naphtalina/iStock via Getty Images Wall Street ended the week on a mixed note as cooler-than-expected September jobs data cut Fed rate-hike odds even as Treasury yield... Full story

Yahoo Finance • last month

Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets

Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spen... Full story

Yahoo Finance • last month

Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration

In late September and early October 2026, AstraZeneca PLC, Daiichi Sankyo and Summit Therapeutics announced a series of clinical collaboration agreements to test ivonescimab in combination with Datroway (datopotamab deruxtecan) and sonesit... Full story

Yahoo Finance • last month

Summit Therapeutics (SMMT), What Is Behind The Fresh Attention?

Summit Therapeutics (SMMT) is back in focus after AstraZeneca agreed to invest about US$2 billion through convertible preferred stock and entered a non exclusive clinical collaboration built around ivonescimab combinations. Summit Therape... Full story

Yahoo Finance • last month

AstraZeneca, Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway-ivonescimab combo

[The answers lie in the evidence] PixelsEffect/iStock via Getty Images * Daiichi Sankyo (DSKYF [https://seekingalpha.com/symbol/DSKYF]) and AstraZeneca entered into a clinical trial collaboration agreement with Summit Therapeutics (SMMT... Full story

Yahoo Finance • last month

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

Collaboration Intends to Evaluate Ivonescimab in Combination with Datroway across Multiple Tumor Types Starting with a Phase III Study in First-Line Triple Negative Breast Cancer MIAMI, October 02, 2026--(BUSINESS WIRE)--Summit Therapeuti... Full story

Yahoo Finance • last month

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

TOKYO, October 02, 2026--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Nasdaq: SMMT) to evaluate Datroway® (datopot... Full story

Yahoo Finance • last month

AstraZeneca (AZN) Puts $2 Billion Into Summit Therapeutics (SMMT) for a Cancer Tie-Up

AstraZeneca PLC (NASDAQ:AZN) said on September 28 that it will make a $2 billion equity investment in Summit Therapeutics, Inc. (NASDAQ:SMMT) and run joint trials of the two companies' cancer drugs. The money buys preferred shares convert... Full story

Yahoo Finance • last month

What Does Summit Therapeutics (SMMT) Gain From This $2 Billion Cancer Partnership?

Summit Therapeutics (NasdaqGM:SMMT) announced a US$2b equity and collaboration agreement with AstraZeneca to advance cancer drug ivonescimab. The partnership includes a new clinical collaboration to study ivonescimab in combination with As... Full story

Yahoo Finance • last month

AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says

AstraZeneca's (AZN) $2 billion investment in Summit Therapeutics (SMMT) is a "win-win" and potential PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), the oncology and biopharmaceutical company, agreed to invest $2 billion in Summit Therapeutics to test new cancer drug combinations. Its shares were down about 0.7% at $164... Full story

Yahoo Finance • last month

Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment

This article first appeared on GuruFocus. Summit Therapeutics (NASDAQ:SMMT), which holds rights to the cancer drug ivonescimab in major markets outside China, rose 16.99% in premarket after AstraZeneca (NYSE:AZN) agreed to invest $2 billi... Full story